India’s NPPA Finalizes Price Caps on 128 Formulations
January 10, 2023
India’s National Pharmaceutical Pricing Authority has announced final price caps for 2023, affecting some 128 formulations. The list includes new ceiling prices for 97 formulations and revised prices for an additional 31. Included on the list are treatments for conditions like seizures, intestinal swelling, heart disease, HIV/AIDS, and more.
According to Monal Sanghvi, “According to an ICICI Securities September 2022 report, a few noteworthy products in the revised list were Amikacin (antibiotic), Cefuroxime (antibiotic), Insulin Glargine (anti-diabetic), Itraconazole (anti-fungal medication), Mupirocin (topical antibiotic) and Teneligliptin (anti-diabetic). The impact of their sale price and on the companies selling these newly-included products is yet to be seen.”
To read more, click here.
(Source: BQ Prime, January 9th, 2023)
